Executive deficits and regional brain metabolism in Alzheimer's disease

2010 ◽  
Vol 25 (11) ◽  
pp. 1150-1158 ◽  
Author(s):  
Benjamin K. P. Woo ◽  
Dylan G. Harwood ◽  
Rebecca J. Melrose ◽  
Mark A. Mandelkern ◽  
Olivia M. Campa ◽  
...  
2010 ◽  
Vol 6 ◽  
pp. S104-S105
Author(s):  
Andreas Fellgiebel ◽  
Matthias Schreckenberger ◽  
Matthias J. Müller ◽  
Ingrid Schermuly ◽  
Peter Stoeter ◽  
...  

2000 ◽  
Vol 21 ◽  
pp. 132
Author(s):  
Mony J. de Leon ◽  
Henry Rusinek ◽  
Alexandra A. Roche ◽  
Adam J. Scherer ◽  
Chaim Y. Tarshish ◽  
...  

Author(s):  
Aviva Ellenstein ◽  
Christina Prather ◽  
Mikhail Kogan

Neurodegenerative diseases increase in prevalence with aging. This chapter begins with a discussion of Parkinson’s disease. Optimally individualized treatment includes dopaminergic medications, physiotherapy, and multidisciplinary care. Evidence for integrative approaches is limited. Advances in genetics and biomarkers hold promise for subtype-specific, precision treatment in the near future. The second part of this chapter focuses on Alzheimer’s disease. Standard evaluation includes assessment for possible contributing factors that may worsen cognition, and management includes optimizing factors that may improve cognitive function. No disease-modifying medical approaches yet exist, but increasing emphasis on interventions to limit chronic inflammation and optimize brain metabolism remain fundamental in the integrative approach to Alzheimer’s disease. The new metabolic approach first described by Dr. Dale Bredesen is summarized and the importance of multidisciplinary care, with emphasis on early transition to palliative care when appropriate, is reviewed.


2006 ◽  
Vol 14 (7S_Part_2) ◽  
pp. P129-P129
Author(s):  
Leon M. Aksman ◽  
Nicholas Firth ◽  
Marzia Antonella Scelsi ◽  
Jonathan M. Schott ◽  
Sebastien Ourselin ◽  
...  

2020 ◽  
Vol 21 (22) ◽  
pp. 8767
Author(s):  
Nicole Jacqueline Jensen ◽  
Helena Zander Wodschow ◽  
Malin Nilsson ◽  
Jørgen Rungby

Under normal physiological conditions the brain primarily utilizes glucose for ATP generation. However, in situations where glucose is sparse, e.g., during prolonged fasting, ketone bodies become an important energy source for the brain. The brain’s utilization of ketones seems to depend mainly on the concentration in the blood, thus many dietary approaches such as ketogenic diets, ingestion of ketogenic medium-chain fatty acids or exogenous ketones, facilitate significant changes in the brain’s metabolism. Therefore, these approaches may ameliorate the energy crisis in neurodegenerative diseases, which are characterized by a deterioration of the brain’s glucose metabolism, providing a therapeutic advantage in these diseases. Most clinical studies examining the neuroprotective role of ketone bodies have been conducted in patients with Alzheimer’s disease, where brain imaging studies support the notion of enhancing brain energy metabolism with ketones. Likewise, a few studies show modest functional improvements in patients with Parkinson’s disease and cognitive benefits in patients with—or at risk of—Alzheimer’s disease after ketogenic interventions. Here, we summarize current knowledge on how ketogenic interventions support brain metabolism and discuss the therapeutic role of ketones in neurodegenerative disease, emphasizing clinical data.


2016 ◽  
Vol 12 ◽  
pp. P399-P400
Author(s):  
Eddie Stage ◽  
Tugce Duran ◽  
Shannon L. Risacher ◽  
Naira Goukasian ◽  
Triet Do ◽  
...  

2016 ◽  
Vol 55 (4) ◽  
pp. 1595-1603 ◽  
Author(s):  
Andrea Slachevsky ◽  
Leonardo Guzmán-Martínez ◽  
Carolina Delgado ◽  
Pablo Reyes ◽  
Gonzalo A. Farías ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document